JOP20180057A1 - مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 - Google Patents

مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Info

Publication number
JOP20180057A1
JOP20180057A1 JOP/2018/0057A JOP20180057A JOP20180057A1 JO P20180057 A1 JOP20180057 A1 JO P20180057A1 JO P20180057 A JOP20180057 A JO P20180057A JO P20180057 A1 JOP20180057 A1 JO P20180057A1
Authority
JO
Jordan
Prior art keywords
tetrahydropyridopyrazine
gpr6
modulators
compound
formula
Prior art date
Application number
JOP/2018/0057A
Other languages
Arabic (ar)
English (en)
Inventor
Todd Macklin
Jason W Brown
Stephen Hitchcock
Shota Kikuchi
Kristin Schleicher
Maria Hopkins
Holger Monenschein
Holly Reichard
Huikai Sun
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of JOP20180057A1 publication Critical patent/JOP20180057A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOP/2018/0057A 2017-06-15 2017-06-15 مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 JOP20180057A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762520430P 2017-06-15 2017-06-15
US201762591247P 2017-11-28 2017-11-28
US201862649856P 2018-03-29 2018-03-29
US201862672261P 2018-05-16 2018-05-16

Publications (1)

Publication Number Publication Date
JOP20180057A1 true JOP20180057A1 (ar) 2019-01-30

Family

ID=64656005

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0057A JOP20180057A1 (ar) 2017-06-15 2017-06-15 مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Country Status (25)

Country Link
US (1) US10406157B2 (https=)
EP (1) EP3638673B9 (https=)
JP (2) JP7460369B2 (https=)
KR (1) KR102802861B1 (https=)
CN (1) CN110730781B (https=)
AU (1) AU2018285677B2 (https=)
CA (1) CA3067032A1 (https=)
CO (1) CO2019015086A2 (https=)
DK (1) DK3638673T3 (https=)
ES (1) ES2988680T3 (https=)
FI (1) FI3638673T3 (https=)
HR (1) HRP20241231T1 (https=)
HU (1) HUE068346T2 (https=)
IL (1) IL271332B2 (https=)
JO (1) JOP20180057A1 (https=)
LT (1) LT3638673T (https=)
MX (1) MX2019014940A (https=)
PH (1) PH12019502792A1 (https=)
PL (1) PL3638673T3 (https=)
PT (1) PT3638673T (https=)
RS (1) RS66018B1 (https=)
SG (1) SG11201912149WA (https=)
SI (1) SI3638673T1 (https=)
TW (1) TWI775874B (https=)
WO (1) WO2018232202A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026067262A1 (zh) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 并环化合物、包含其的药物组合物及其用途和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7229557B2 (en) 2004-02-04 2007-06-12 Konec, Inc. Method to separate stereoisomers
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Gpr6のピリドピラジンモジュレーター
KR20160122215A (ko) * 2014-02-14 2016-10-21 다케다 야쿠힌 고교 가부시키가이샤 Gpr6의 피라진 조절제

Also Published As

Publication number Publication date
EP3638673A4 (en) 2021-03-24
PT3638673T (pt) 2024-10-07
IL271332A (en) 2020-01-30
RS66018B1 (sr) 2024-11-29
EP3638673A1 (en) 2020-04-22
MX2019014940A (es) 2020-02-19
KR102802861B1 (ko) 2025-04-30
JP2022188199A (ja) 2022-12-20
FI3638673T3 (fi) 2024-09-13
LT3638673T (lt) 2024-09-10
HUE068346T2 (hu) 2024-12-28
CA3067032A1 (en) 2018-12-20
KR20200014796A (ko) 2020-02-11
IL271332B (en) 2022-10-01
ES2988680T3 (es) 2024-11-21
US20180360831A1 (en) 2018-12-20
SI3638673T1 (sl) 2025-01-31
TWI775874B (zh) 2022-09-01
WO2018232202A1 (en) 2018-12-20
AU2018285677A1 (en) 2019-12-19
BR112019026430A2 (pt) 2020-07-14
EP3638673B9 (en) 2024-11-20
EP3638673B1 (en) 2024-07-17
CO2019015086A2 (es) 2020-04-13
AU2018285677B2 (en) 2022-07-14
TW201906844A (zh) 2019-02-16
JP7497400B2 (ja) 2024-06-10
SG11201912149WA (en) 2020-01-30
JP7460369B2 (ja) 2024-04-02
NZ759708A (en) 2024-04-26
HRP20241231T1 (hr) 2024-12-20
JP2020523287A (ja) 2020-08-06
CN110730781B (zh) 2023-05-05
PL3638673T3 (pl) 2024-11-18
IL271332B2 (en) 2023-02-01
RU2019144408A (ru) 2021-07-15
US10406157B2 (en) 2019-09-10
CN110730781A (zh) 2020-01-24
DK3638673T3 (da) 2024-09-16
PH12019502792A1 (en) 2020-09-14
RU2019144408A3 (https=) 2021-09-07

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
EP4365179A3 (en) Novel rapamycin derivatives
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018501068A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ747259A (en) Soluble c5ar antagonists
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
EP4609866A3 (en) Oxysterols and methods of use thereof
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
EP4316591A3 (en) Oxysterols and methods of use thereof
AU2018253590A1 (en) Imidazopyridazine compounds
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
EP4599887A3 (en) Oxysterols and methods of use thereof
NZ759295A (en) 5-5 fused rings as c5a inhibitors
TN2017000144A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
EP4494705A3 (en) Non-peptide oxytocin receptor agonists